Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ABAX --- lots of upside -- Ignore unavailable to you. Want to Upgrade?

To: Richard Birk who wrote (463)	11/11/1998 1:05:00 PM
From: David Bogdanoff	Read Replies (1) \| Respond to of 492

R; The total market for blood analysis is huge; I recall reading figures in 5-7 billion range. ABAX aims at the point of care niche of this market and this market is much smaller (less than 5% I would safely guess). ABAX is currently trying to expand production to meet this market and increase margins. Its problem is more one of developing automated production; its products are readily accepted among veternarians and will expand more in the much larger human clinical market when it completes development of its electrolyte products. This small niche will expand as the higher direct cost of its system comes down and its convenience and speed advantages become appreciated. All imho. David